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Abstract
 
Interleukin (IL)-7 is essential for normal T cell development. Previously, we have shown that
IL-7 increases viability and proliferation of T cell acute lymphoblastic leukemia (T-ALL) cells
by up-regulating Bcl-2 and down-regulating the cyclin-dependent kinase inhibitor p27
 
kip1
 
.
Here, we examined the signaling pathways via which IL-7 mediates these effects. We investi-
gated mitogen-activated protein kinase (MEK)–extracellular signal-regulated kinase (Erk) and
phosphatidylinositol-3-kinase (PI3K)–Akt (protein kinase B) pathways, which have active roles
in T cell expansion and have been implicated in tumorigenesis. IL-7 induced activation of the
MEK–Erk pathway in T-ALL cells; however, inhibition of the MEK–Erk pathway by the use
of the cell-permeable inhibitor PD98059, did not affect IL-7–mediated viability or cell cycle
progression of leukemic cells. IL-7 induced PI3K-dependent phosphorylation of Akt and its
downstream targets GSK-3, FOXO1, and FOXO3a. PI3K activation was mandatory for IL-7–
mediated Bcl-2 up-regulation, p27
 
kip1 
 
down-regulation, Rb hyperphosphorylation, and conse-
quent viability and cell cycle progression of T-ALL cells. PI3K signaling was also required for
cell size increase, up-regulation of CD71, expression of the glucose transporter Glut1, uptake
of glucose, and maintenance of mitochondrial integrity. Our results implicate PI3K as a major
effector of IL-7–induced viability, metabolic activation, growth and proliferation of T-ALL
cells, and suggest that PI3K and its downstream effectors may represent molecular targets for
therapeutic intervention in T-ALL.
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Introduction
 
IL-7–mediated signals are linked to survival and cell cycle
progression (1). In normal T cell development, IL-7 plays a
nonredundant role as an antiapoptotic factor by up-regulating
Bcl-2 expression (1). Similar to normal immature thy-
mocytes, leukemic blasts from T cell acute lymphoblastic
leukemia (T-ALL), patients can express functional IL-7Rs
(2). Moreover, different studies demonstrated that IL-7 can
induce proliferation and prevent spontaneous apoptosis of
T-ALL cells in vitro (2, 3). Importantly, IL-7 is present in
the microenvironments where the leukemia arises because
it is produced by thymic epithelial and bone marrow stromal
cells (4, 5), and significantly contributes to the increased
survival of T-ALL cells cocultured with thymic epithelial
cells (6). These data suggest that IL-7 may play an important
role in the biology of T-ALL. We have shown previously
that IL-7 down-regulates the expression of the cyclin-
dependent kinase (cdk) inhibitor p27
 
kip1
 
, leading not only
to cell cycle progression but also to up-regulation of Bcl-2
protein expression and viability of T-ALL cells (7). Further-
more, IL-7 can support the long-term expansion of pri-
mary T-ALL cells, as shown by the establishment an IL-7–
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dependent cell line (TAIL7) that maintains the essential
features of IL-7–responsive primary T-ALL blasts (8).
Mitogen-activated protein kinase (MEK)–extracellular
signal-regulated kinase (Erk) (MEK–Erk) signals have been
shown to promote viability (9) and induce cell cycle pro-
gression by regulating the expression of c-Myc, cyclin
D1, p27
 
kip1
 
, and p21
 
cip1 
 
(10). Phosphatidylinositol-3-kinase
(PI3K) and Akt/protein kinase B (hereafter referred to as
Akt) have also been associated with prevention of apoptosis
and cell cycle progression (11–13). These effects are impli-
cated in PI3K–Akt-mediated tumorigenesis (12, 14–16).
Strikingly, Jurkat and other T cell leukemia cell lines lack
PTEN and/or SHIP, and consequently have high PI3K and
Akt basal activities (17). Both MEK–Erk and PI3K–Akt
pathways are involved in T cell survival, expansion, and dif-
ferentiation (18–22). However, IL-7 appears to activate
PI3K–Akt but not MEK–Erk in normal T cells (18, 23).
Our present studies demonstrate that IL-7 activated the
MEK–Erk pathway in T-ALL cells, contrary to what oc-
curs in normal T cells (18, 23). However, MEK–Erk did
not appear to be essential for IL-7–mediated viability and
proliferation of T-ALL cells. IL-7 also triggered PI3K-
dependent phosphorylation of Akt, GSK-3, FOXO1, and
FOXO3a. Inhibition of PI3K prevented up-regulation of
Bcl-2, down-regulation of p27
 
kip1
 
, and hyperphosphoryla-
tion of Rb, and abrogated IL-7–mediated survival and pro-
liferation of T-ALL cells. IL-7 induced expression of the
glucose transporter Glut1 in a PI3K-dependent fashion,
and this event correlated with glucose use, mitochondrial
integrity, increase of cell size, and up-regulation of CD69
and CD71. These results demonstrate that PI3K down-
stream signals are fundamental for IL-7–mediated survival,
activation, proliferation, and growth of T-ALL cells, and
may regulate clonal expansion of T cell acute leukemia.
 
Materials and Methods
 
Primary T-ALL Samples and the TAIL7 Cell Line.
 
T-ALL
cells were obtained from the peripheral blood and/or the bone
marrow of patients with high leukemia involvement (85–100%).
Informed consent and Institutional Review Board approval was
obtained for all sample collections. Samples were enriched by
density centrifugation over Ficoll-Hypaque, washed twice in
RPMI 1640 supplemented with 10% (vol/vol) FBS and 2 mM
 
l
 
-glutamine (hereafter referred to as RPMI 10 medium), subjected
to immunophenotypic analysis by flow cytometry as described
previously (7), and classified according to their maturation stage
using the criteria defined by the European Group for Immuno-
logical Characterization of Leukemias (see Table I; reference 24).
The TAIL7 cell line was established from the peripheral blood of
a pediatric T-ALL patient. It is IL-7 dependent and has been de-
scribed previously (8).
 
In Vitro Culture.
 
Primary T-ALL or TAIL7 cells isolated by
density centrifugation over Ficoll-Hypaque were cultured in 24-
well plates at 2 
 
  
 
10
 
6 
 
cells/ml at 37
 
 
 
C with 5% CO
 
2 
 
in the fol-
lowing: RPMI 10 (control medium), 10 ng/ml IL-7 (Endogen),
IL-7 plus 10 
 
 
 
M MEK-specific inhibitor PD98059 (Calbio-
chem), or IL-7 plus 10 
 
 
 
M PI3K-specific inhibitor LY294002
(Calbiochem). At the indicated time points, cells were harvested
and processed as indicated below for assessment of viability, acti-
vation, cell cycle progression, and preparation of lysates for West-
ern blotting. TAIL7 cells were previously starved in RPMI 10
without IL-7 for 5–7 d or in RPMI without FBS for 1–4 d, with
similar results.
 
Proliferation Assays.
 
Cells were cultured in triplicates in flat-
bottom 96-well plates at 2 
 
  
 
10
 
6 
 
cells/ml at 37
 
 
 
C with 5% CO
 
2
 
in RPMI 10 without any cytokine or in the experimental condi-
tions mentioned above. Cells were incubated with [
 
3
 
H]thymidine
(1 
 
 
 
Ci/well) for 16 h before harvest. DNA synthesis, as measured
by [
 
3
 
H]thymidine incorporation, was assessed using a liquid scin-
tillation counter. Average and standard deviation of triplicates
were calculated.
 
Assessment of Cell Viability, Size, and Activation.
 
Quantitative
determination of viability of the malignant cells was performed
using an annexin V–based apoptosis detection kit (R&D Sys-
tems), as described previously (7). Cell size was assessed by analy-
sis of SSC versus FSC flow cytometry plots gated on the live cell
population. Surface expression of activation markers CD71 and
CD69 was measured by flow cytometry using FITC-conjugated
anti-CD71 (DakoCytomation) and PE-conjugated anti-CD69
(Beckman Coulter) antibodies and appropriately matched isotype
controls. Samples were analyzed using a FACSCalibur flow cy-
tometer and CELLQuest software (Becton Dickinson). Results
were expressed as the percentage of positive cells as compared
with the negative control, and as the specific mean intensity of
fluorescence (MIF), defined as the ratio of MIF of the specific an-
tibody stain over the MIF of negative control antibody.
 
Cell Cycle Analysis.
 
Determination of the percentage of cells
at each stage of the cell cycle was performed by assessment of
DNA content after staining with propidium iodide. In brief, 5 
 
 
 
10
 
5 
 
cells per sample were resuspended in 0.5 ml PBS and then
fixed with ice-cold 80% ethanol. Propidium iodide was added at
a final concentration of 2.5 
 
 
 
g/ml, ribonuclease A was added at
50 
 
 
 
g/ml, and samples were incubated for 30 min at 37
 
 
 
C in the
dark. Analysis of flow cytometry cell cycle histograms was per-
formed using ModFit LT software (Verity).
 
Short-Term Stimulation with IL-7.
 
For the initial experiments,
IL-7–deprived TAIL7 cells were washed twice with PBS and incu-
bated for the indicated periods at 37
 
 
 
C with prewarmed PBS alone
or with the indicated concentrations of IL-7. IL-7–deprived
TAIL7 cells were then incubated for 15 min at 37
 
 
 
C with PBS
alone or with 50 ng/ml IL-7. In defined experiments, the cells
were pretreated in PBS with 10 
 
 
 
M LY294002, 10 
 
 
 
M PD98059,
or the corresponding volume of vehicle (DMSO) for 2 h before
stimulation. Reactions were stopped by placing samples on ice and
adding ice-cold PBS. Cells were washed twice with cold PBS and
lysates were prepared for Western blot analysis (immunoblotting).
 
Immunoblotting, Immunoprecipitation, and In Vitro Kinase Reac-
tions.
 
After the indicated conditions and time intervals of
culture, cell lysates were prepared and equal amounts of pro-
tein were analyzed by 10% SDS-PAGE, transferred onto nitro-
cellulose membranes, and immunoblotted with the following
mAbs or antiserum: p27
 
kip1 
 
(BD Transduction Laboratories), actin,
STAT5, and Glut1 (Santa Cruz Biotechnology, Inc.), ZAP-70
and phospho-STAT5A/B (Y694/Y699; Upstate Biotechnology),
and phospho-Akt (S473), phospho-GSK-3
 
 
 
 (S9), phospho-
FKHR(FOXO1) (T24)/phospho-FKHRL1(FOXO3a) (T32),
phospho-MEK1/2 (S217/S221), phospho-Erk1/2 (T202/Y204),
Akt, and Erk1/2 (Cell Signaling Technology). To examine the
phosphorylation status of Rb, proteins were analyzed by 6%
SDS-PAGE, transferred onto nitrocellulose membrane, and blot-
ted with Rb-specific mAbs (BD Biosciences). After immunoblot- 
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ting with mAbs or antiserum, immunodetection was performed
by incubation with horseradish peroxidase–conjugated anti–
mouse IgG (1:5,000), anti–rabbit IgG (1:10,000), or anti–goat
IgG (1:5,000; Promega), as indicated by the host origin of the
primary antibody and developed by chemiluminescence (Amer-
sham Biosciences).
Akt in vitro kinase reactions were performed using a nonra-
dioactive Akt kinase assay kit purchased from Cell Signaling
Technology according to the manufacturer’s instructions. In
brief, cell lysates with equal amounts of protein were immuno-
precipitated using agarose hydrazide–conjugated Akt antibody,
washed twice, and resuspended in kinase buffer supplemented
with 200 
 
 
 
M cold ATP. Kinase reactions were performed using
paramyosin-crosstide GSK-3
 
 
 
/
 
  
 
fusion protein as exogenous
substrate. Reactions were analyzed by 12% SDS-PAGE, trans-
ferred to nitrocellulose membrane, and GSK-3 phosphoryla-
tion was detected by immunoblotting with phospho-GSK-3
 
 
 
/
 
 
 
(Ser21/Ser9) antibody. Even loading was confirmed by stripping
and reprobing the membranes with an Akt antibody (Cell Signal-
ing Technology). Relative quantification of Western blot bands
was performed by densitometry analysis using ImageQuant Image
Analysis software (Amersham Biosciences).
 
Intracellular Staining.
 
Bcl-2 protein expression was assessed by
intracellular staining. Cells were fixed in 0.1% formaldehyde for
30 min at 4
 
 
 
C, washed in PBS, resuspended in 1
 
  
 
Perm/Wash
Solution (BD Biosciences), and incubated with mouse monoclo-
nal FITC-conjugated anti–Bcl-2 antibody (DakoCytomation).
Irrelevant isotype-matched antibody was used as negative control.
Samples were analyzed by flow cytometry. Results were ex-
pressed as the percentage of positive cells in comparison to the
negative control, and as specific MIF.
 
Assessment of Mitochondrial Membrane Potential (
 
 
 
 
 
m
 
).
 
Cells
were harvested, stained in culture medium with TMRE (Sigma-
Aldrich) to a final concentration of 100 nM, and incubated for 30
min at 37
 
 
 
C with 5% CO
 
2
 
. CCCP (Sigma-Aldrich) was added to
duplicate tubes to a final concentration of 50 
 
 
 
M to collapse 
 
 
 
 
 
m
 
and therefore validate the assay and serve as a control for back-
ground levels of fluorescence. Cells were analyzed for TMRE in-
tensity by flow cytometry.
 
Glucose Uptake Assay.
 
After the indicated culture conditions,
10
 
6 
 
TAIL7 cells were starved in PBS at room temperature for
30 min and incubated at 37
 
 
 
C for 10 min in PBS containing 5
 
 
 
M 2-{
 
14
 
C(U)}-deoxy-
 
d
 
-glucose (PerkinElmer). Cells were har-
vested on filtermats and counted for 
 
14
 
C-glucose content. Aver-
age and standard deviation of triplicates were calculated.
 
Online Supplemental Material.
 
In Fig. S1, primary T-ALL cells
were cultured with 10 ng/ml IL-7, either alone or in the pres-
ence of 10 
 
 
 
M PD098059 or 10 
 
 
 
M LY294002. Viability and
proliferation were assessed as described above. Fig. S1 is available
at http://www.jem.org/cgi/content/full/jem.20040789/DC1.
 
Results
 
IL-7 Activates MEK–Erk and PI3K–Akt Pathways in
T-ALL Cells.
 
PI3K–Akt and MEK–Erk pathways are
thought to play an active role in normal thymocyte and
mature T cell expansion (18–20). For this reason we inves-
tigated whether these pathways are involved in IL-7–medi-
ated proliferation and viability of T-ALL cells that we have
previously reported. We used both primary T-ALL samples
and TAIL7, a cell line that displays IL-7–mediated re-
sponses identical to primary leukemia cells (8) and provides
a useful tool for experiments that require high cell numbers
that cannot be obtained using primary leukemia cells. Cy-
tokine-deprived TAIL7 cells were stimulated by 50 ng/ml
Figure 1. IL-7 activates MEK–Erk and PI3K–Akt pathways in T-ALL.
IL-7–deprived TAIL7 cells were stimulated with IL-7 for the indicated
periods (A and B). Cell lysates were resolved with 10% SDS-PAGE and im-
munoblotted with the indicated antibodies. Results representative of three in-
dependent experiments are shown. Levels of phosphorylated MEK1/2 and
Erk1/2 were detected with antisera that selectively recognize the activated
forms of the following kinases: Ser217/Ser221-phosphorylated MEK1/2
(P-MEK1/2) and Thr202/Tyr204-dual-phosphorylated Erk1/2 (P-Erk1/2).
Levels of phosphorylated Akt and GSK-3 were analyzed with antibodies that
specifically recognize Ser473-phosphorylated Akt (P-Akt) and Ser9-phos-
phorylated GSK-3  (P-GSK-3 ), respectively. Levels of phosphorylated
FOXO1/FOXO3a were detected with antiserum that reacts with Thr24-
phosphorylated FOXO1 (P-AFOXO1) and Thr32-phosphorylated FOXO3a
(P- FOXO3a). Akt and Erk1/2 protein levels were assessed with specific an-
tibodies and remained unchanged (not depicted). Blots were reprobed with
an anti–ZAP-70 antibody to confirm even protein loading. (C) IL-7 activates
Akt and induces in vitro phosphorylation of GSK-3 by Akt. IL-7–deprived
TAIL7 cells were stimulated with IL-7 for 15 min. To compare Akt enzy-
matic activity in unstimulated (Unst.) versus IL-7–stimulated cells (IL-7), cell
lysates were immunoprecipitated with agarose-conjugated anti-Akt antibody
and in vitro kinase reactions were performed using crosstide-GSK-3 /  as
exogenous substrate. Reactions were analyzed by 12% SDS-PAGE, trans-
ferred to nitrocellulose membrane, and GSK-3 phosphorylation was detected
by immunoblotting with anti–phospho-GSK-3 /  (Ser21/Ser9) antibody.
Even loading was confirmed with an anti-Akt antibody. Relative quantifica-
tion of phosphorylated GSK-3  and GSK-3  bands was performed by densi-
tometry analysis. Results were normalized in relation to the loading control
(Akt) and expressed as relative units. IL-7 induced a 1.63-fold increase in
GSK-3  and a 3.07-fold increase in GSK-3  Akt-mediated phosphorylation.
Results are representative of two independent experiments. 
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IL-7 for increasing periods of time for up to 120 min, and
protein phosphorylation was assessed by Western blot.
Erk1/2 was phosphorylated and activated upon IL-7 stimu-
lation of TAIL7 cells, as determined by immunoblotting
with an antibody that exclusively detects Erk1/2 when cat-
alytically activated by phosphorylation at both Thr202 and
Tyr204. Phosphorylation of Erk1/2 was detectable after 5
min of stimulation, increased at 15 min, peaked by 30 min
(Fig. 1 A), and was still detected by 2 h of stimulation (not
depicted). A similar pattern of phosphorylation was ob-
served for MEK1/2 (Fig. 1 A). When TAIL7 cells were
stimulated with increasing doses of IL-7, phosphorylation
of MEK and Erk was detected with 1 ng/ml and reached a
plateau at 10 ng/ml (not depicted).
Next, we analyzed whether IL-7 activated the PI3K–Akt
pathway in TAIL7 cells. Phosphorylation of Akt at Ser473,
which is necessary for full activation of Akt kinase, oc-
curred within 1 min, peaked at 30 min, and was undetect-
able after 1 h of IL-7 stimulation (Fig. 1 B). Members of
the FOXO family of transcription factors are direct targets
of Akt (25). In TAIL7 cells, IL-7 induced phosphorylation
of FOXO1 (at Thr24) and FOXO3a (at Thr32) in a time-
dependent manner (Fig. 1 B). FOXO1 phosphorylation at
Ser256 did not appear to be regulated by IL-7 in these cells
(not depicted). GSK-3, another known downstream target
of Akt, was also phosphorylated by stimulation with IL-7
(Fig. 1 B). IL-7 mediated a dose-dependent phosphoryla-
tion of Akt and its downstream targets, which was detected
at 
 
 
 
1 ng/ml and reached a plateau at 10 ng/ml (not de-
picted). These results suggest that Akt becomes enzymati-
cally active after stimulation with IL-7. To confirm that IL-7
can induce the enzymatic activity of Akt in TAIL7 cells, ly-
sates from unstimulated or 15 min IL-7–stimulated cells
were immunoprecipitated with an anti-Akt antibody and
an in vitro kinase reaction was performed using GSK-3
 
 
 
/
 
 
 
as exogenous substrate. Phosphorylation of GSK-3
 
 
 
, and
more prominently of GSK-3
 
 
 
, was up-regulated (1.6- and
threefold, respectively) by stimulation with IL-7 (Fig. 1 C).
These results confirm that IL-7 induced Akt phosphoryla-
tion, leading to its enzymatic activation and consequent
phosphorylation of GSK-3.
Because we observed that phosphorylation of Akt, GSK-3,
and FOXO family members was mediated by IL-7, we
sought to confirm that these events were dependent upon
PI3K activation. IL-7–deprived TAIL7 cells were pretreated
with 10 
 
 
 
M of the cell-permeable PI3K-specific inhibitor
LY294002 or MEK-specific inhibitor PD98059 before IL-7
stimulation. LY294002 specifically abrogated phosphoryla-
tion of Akt, without affecting phosphorylation of Erk1/2
or STAT5, whereas PD98059 specifically inhibited phos-
phorylation of Erk1/2 without affecting phosphorylation of
Akt or STAT5 (Fig. 2 A). Furthermore, LY294002 but not
PD98059 inhibited GSK-3, FOXO1, and FOXO3a phos-
phorylation (Fig. 2 B). These findings indicate that IL-7–
induced phosphorylation of Akt and downstream targets in
T-ALL cells are dependent on PI3K activity and can be
specifically disrupted by LY294002.
 
PI3K But Not MEK Is Required for IL-7–mediated Increase
in Viability and Cell Cycle Progression of T-ALL Cells.
 
To
analyze the functional role of PI3K–Akt and MEK–Erk ac-
tivation by IL-7 in T-ALL cells, we investigated the ef-
fect of specific inhibition of these pathways on IL-7–medi-
ated viability and proliferation of TAIL7 cells by using
LY294002 and PD98059. Initial experiments determined
that IL-7 stimulated a dose-dependent increase in viability
and proliferation of TAIL7 cells, which was most evident
between 72 and 96 h of culture with 10 ng/ml IL-7 (not
depicted). Therefore, we used this concentration and time
points in all subsequent experiments. Staining of leukemic
cells with annexin V–FITC and propidium iodide followed
by flow cytometry analysis revealed that LY294002 inhib-
ited IL-7–mediated increase in the percentage of viable
cells, whereas PD98059 showed no effect (Fig. 3 A). The
same pattern was obtained when we examined cell prolifer-
ation by assessing the incorporation of [
 
3
 
H]thymidine. As
shown in Fig. 3 B, PD98059 did not affect proliferation of
IL-7–cultured TAIL7 cells. In contrast, LY294002 com-
pletely abrogated IL-7–induced proliferation (Fig. 3 B).
Next, we examined whether inhibition of PI3K prevented
Figure 2. IL-7 induces PI3K-dependent phosphorylation of Akt,
GSK-3, FOXO1, and FOXO3a, and MEK-dependent phosphorylation
of Erk1/2 in T-ALL cells. IL-7–deprived TAIL7 cells were pretreated
with 10  M LY294002 (LY) or 10  M PD098059 (PD) for 2 h, and
then stimulated with IL-7 for 15 min. (A) Western blot analysis was per-
formed with P-Erk1/2, P-Akt antibodies (see legend to Fig. 1), and an anti-
body specific for Tyr694/Tyr699-phosphorylated-STAT5A/B (P-STAT5)
to confirm that LY294002 and PD98059 were specific inhibitors of the
PI3K–Akt and MEK–Erk pathway, respectively. (B) GSK-3 , FOXO1,
and FOXO3a phosphorylation is dependent on PI3K activity. Western
blot analysis was performed with P-Akt, P-GSK3 , and P-FOXO1/
FOXO3a antibodies. Anti-STAT5 (A) and actin (B) antibodies were used
to confirm equal loading. Representative results from three independent
experiments are shown. 
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[
 
3
 
H]thymidine incorporation only because it impaired cell
viability, or whether it also blocked cell cycle progression.
TAIL7 cells were fixed and stained with propidium iodide
and analyzed for cell cycle progression by flow cytometry.
As shown in Fig. 2 C, the PI3K inhibitor LY294002 abro-
gated cell cycle progression of IL-7–cultured cells, whereas
the MEK inhibitor PD98059 had no effect. Thus, PI3K
seems to have a dominant role in IL-7–mediated viability
and cell cycle progression in TAIL7 leukemia cells.
To confirm the biological significance of these results
obtained in TAIL7 cells, we examined whether PI3K
played a similar critical role on IL-7–mediated effects in
primary T-ALL cells. Leukemic cells were collected from
the peripheral blood or bone marrow of pediatric T-ALL
patients with high leukemia involvement and tested for in
vitro responsiveness to IL-7 by assessing cellular prolifera-
tion. IL-7–responsive samples were immunophenotyped,
classified according to their maturation stage (Table I), and
used in subsequent experiments. The increase in viability
(Fig. 3 D and Fig. S1, available at http://www.jem.org/
cgi/content/full/jem.20040789/DC1) and proliferation
(Fig. 3 E and Fig. S1) induced with IL-7 was completely
abrogated by LY294002, whereas PD98059 had no signifi-
cant impact on IL-7–mediated effects in primary leukemia
cells. Our data demonstrate that PI3K is indispensable for
both viability and proliferation mediated by IL-7 not only
in the TAIL7 line, but also in primary T-ALL cells. In con-
trast, MEK–Erk pathway albeit activated by IL-7 does not
appear to play a functionally significant role in mediating
these effects of IL-7 in T-ALL.
 
IL-7–mediated Down-regulation of p27
 
kip1
 
, Hyperphosphory-
lation of Rb, and Up-regulation of Bcl-2 in T-ALL Cells Is De-
pendent upon PI3K Activity.
 
Cell cycle progression from
G0/G1 to S phase is modulated by exogenous factors and
is positively regulated by cyclin–cdk holoenzymes, which
phosphorylate several intracellular substrates including Rb.
Phosphorylation and inactivation of Rb result in release of
E2F and transcription of genes that are required for progres-
sion through S phase (26). The enzymatic activity of cyclin–
cdk complexes is negatively regulated by cdk inhibitors,
including the cip/kip family member p27
 
kip1 
 
(27). We pre-
viously demonstrated that culture with IL-7 down-regulates
p27
 
kip1 
 
protein expression, resulting in cdk activation, ensu-
ing hyperphosphorylation of Rb, and cell cycle progression
(7). Because LY294002 inhibited IL-7–regulated cell cycle
progression, we next evaluated whether PI3K-dependent
events could link IL-7 to the cell cycle machinery. Culture
of TAIL7 cells with IL-7 for 96 h resulted in down-regula-
tion of p27
 
kip1 
 
(Fig. 4 A) and hyperphosphorylation of Rb
(Fig. 4 B). LY294002 completely reversed these IL-7–medi-
ated effects, up-regulating p27
 
kip1 
 
to the same levels as those
Figure 3. PI3K but not MEK is critical for IL-7–mediated viability and
cell cycle progression of T-ALL cells. (A–C) TAIL7 cells were cultured
for 96 h with 10 ng/ml IL-7, either alone or in the presence of 10  M
PD098059 (IL-7 PD) or 10  M LY294002 (IL-7 LY). (A) TAIL7 cells
were stained with annexin V–FITC plus propidium iodide and viability
was determined by flow cytometry analysis. (B) Proliferation was deter-
mined by assessment of [3H]thymidine incorporation. (C) Percentage of
cells at S G2/M phases of the cell cycle was determined by propidium
iodide staining followed by flow cytometry analysis. (D and E) Primary
T-ALL cells were obtained as described in Materials and Methods, and
cultured under the indicated conditions. Viability at 96 h (D) and prolif-
eration at 72 h (E) of culture were assessed as described for TAIL7 cells.
Results are representative of three to six independent experiments with
TAIL7 cell line and two independent experiments with all five primary
T-ALL samples. Results from remaining primary T-ALL samples are
shown in Fig. S1.
 
Table I.
 
Immunophenotype and Classification of T-ALL Patients
 
Immunophenotype
T-ALL no. CD1 CD2 CD3 CD4 CD5 CD7 CD8 CD10 CD14 CD19 CD33 CD34 CD56 Maturation stage
1
 
                   
 
III
2
 
                   
 
III
3
 
                   
 
II
4
 
         
 
ND ND
 
  
 
ND III
5                     II
T cell maturation stages of primary samples were defined as described previously (reference 24). Stage II, pre–T-ALL; stage III, cortical T-ALL.Regulation of T-ALL Growth via PI3K–Akt 664
presented by leukemic cells cultured in medium alone, and
preventing Rb hyperphosphorylation. MEK inhibition us-
ing PD98059 did not affect p27kip1 levels or Rb phosphory-
lation (not depicted). Similar results were observed for pri-
mary T-ALL cells (Fig. 4, C and D). These results indicate
that PI3K activation is essential for IL-7 to induce p27kip1
down-regulation and cell cycle progression in T-ALL cells.
Prevention of spontaneous apoptosis of in vitro–cultured
primary T-ALL cells by IL-7 was shown to correlate with
increased Bcl-2 protein expression (3). We subsequently
demonstrated that Bcl-2 up-regulation was mandatory for
IL-7–mediated promotion of viability. Moreover, we ob-
served a causative link between p27kip1 down-regulation and
increase in Bcl-2 expression (7). Because the addition of
LY294002 completely blocked IL-7–mediated viability of
T-ALL cells, we examined whether IL-7 regulated Bcl-2
via activation of PI3K. TAIL7 cells were cultured with ei-
ther medium alone, IL-7, or IL-7 plus LY294002. After 96 h,
cells were analyzed for intracellular expression of Bcl-2
by flow cytometry. IL-7–mediated up-regulation of Bcl-2
was significantly impaired by LY294002 (Fig. 4 E). Primary
T-ALL samples showed similar results (Fig. 4 F). Thus, up-
regulation of Bcl-2 mediated by IL-7 in T-ALL cells re-
quires activation of PI3K.
IL-7 Induces Increased Cell Size and Activation of T-ALL
Cells in a PI3K-dependent Manner. T cell activation can be
measured by increased cell size (cell growth) and by the
surface expression of CD69 and CD71. After 72 h of cul-
ture, IL-7 strikingly up-regulated cell size of TAIL7 cells
Figure 4. IL-7 mediates p27kip1 down-regulation, Rb hyperphosphory-
lation, and Bcl-2 up-regulation via activation of PI3K in T-ALL cells.
TAIL7 cells (A and B) or primary T-ALL cells (C and D) were cultured
for 96 or 72 h, respectively, under the indicated conditions. (A and C)
Cell lysates were resolved by 10% SDS-PAGE and immunoblotted with
anti-p27kip1 antibody. Membranes were stripped and reprobed with ZAP-
70 to confirm equal loading. (B and D) Lysates from the same samples
were analyzed by 6% SDS-PAGE and immunoblotted with an Rb-specific
antibody. The hyperphosphorylated form of Rb corresponds to the band
with the higher apparent molecular weight. Blasts from T-ALL number 3
were used in this experiment. (E) Bcl-2 protein levels at 96 h of culture
were assessed by flow cytometry after intracellular staining of TAIL7 cells
with FITC-conjugated anti–Bcl-2 antibody. (F) Expression of Bcl-2 in
primary T-ALL cells was assessed at 72 h of culture. Results are represen-
tative of four different patient samples analyzed. Specific MIF, as described in
Materials and Methods, is indicated in each histogram. Results were similar in
six independent experiments.
Figure 5. PI3K is critical for IL-7–mediated cell growth and activation
of T-ALL cells. TAIL7 (A) and primary T-ALL (B) cells were cultured
for 72 h in medium alone or with 10 ng/ml IL-7, and then analyzed by
flow cytometry for changes in cell size (determined by FSC) in the live
cell population. Percentage of “activated” cells was calculated by defining
a threshold gate that excluded the bulk, small-sized population of medium-
cultured cells. Results from one representative patient of five tested are
shown in B. Results shown in A are similar to those found in numerous
independent experiments. TAIL7 cells (C) and primary T-ALL cells (D)
were cultured for 96 h under the indicated conditions, and the percentage
of activated cells was calculated. TAIL7 cells cultured for 96 h (E) and pri-
mary T-ALL cells cultured for 72 h (F) under the indicated conditions
were stained with anti-CD71 antibody. Results were expressed as the
percentage of positive cells and as the specific MIF (in brackets). Results
from primary T-ALL cells and the TAIL7 cell line were similar in three
independent experiments.Barata et al. 665
(Fig. 5 A), consistently with previous results (8). Likewise,
IL-7 increased cell size in all primary T-ALL samples (five
cases analyzed; Fig. 5 B). To determine which intracellular
pathways were involved in mediating IL-7–induced
growth of T-ALL cells, we blocked PI3K–Akt and MEK–
Erk pathways with the specific inhibitors. LY294002 com-
pletely inhibited or greatly impaired IL-7–mediated in-
crease of cell size in TAIL7 (Fig. 5 C) and in primary
T-ALL cells (Fig. 5 D). In contrast, PD98059 induced only
a minor decrease in the percentage of activated cells.
Next, we used TAIL7 (Fig. 5 E) and primary T-ALL cells
(Fig. 5 F) to compare the surface expression of activation
markers CD71 and CD69 between medium- and IL-7–cul-
tured cells. Flow cytometry analysis revealed that both CD71
(Fig. 5, E and F) and CD69 (not depicted) were strongly up-
regulated by IL-7. Consistently with the effects on IL-7–
mediated cell size increase, LY294002, but not PD985002,
completely inhibited IL-7–mediated surface expression of
CD71 in TAIL7 cells (Fig. 5 E) and primary T-ALL cells
(Fig. 5 F), as assessed by both specific MIF and percentage of
CD71  cells. Similar results were obtained with CD69 (not
depicted). These results indicate that the MEK–Erk pathway
does not significantly affect IL-7–mediated cell growth and
activation of T-ALL cells, whereas PI3K-dependent signal-
ing is critical for the regulation of these effects.
IL-7 Induces Glut1 Expression and Promotes Glucose Uptake
by T-ALL Cells. Activation and growth of normal T cells
is associated with increased glycolysis (28). Cytokines can
induce expression of glucose transporters (29, 30) and aug-
ment glucose uptake (31) and glycolytic rates (32). The
PI3K–Akt pathway is specifically involved in these pro-
cesses in normal T lymphocytes (29). Because PI3K had a
critical role in IL-7–mediated promotion of viability and
induced cell growth and activation of T-ALL cells, we ex-
amined whether this correlated with the expression of the
glucose transporter Glut1. As shown in Fig. 6 A, IL-7 up-
regulated Glut1 in TAIL7 cells and this effect was depen-
dent on PI3K activity because it was abrogated by the use
of LY (Fig. 6 A). Subsequent to PI3K-dependent induction
of Glut1 expression, IL-7 also increased glucose uptake by
TAIL7 cells (Fig. 6 B). Thus, IL-7 provides the machinery
for nutrient use by T-ALL cells and this effect is mediated
in a PI3K-dependent manner.
IL-7 Regulates Mitochondrial Homeostasis in a PI3K-depen-
dent Manner in T-ALL Cells. Glucose metabolism, simi-
larly to antiapoptotic Bcl-2 family members, can maintain
mitochondrial integrity and homeostasis (30), and conse-
quently negatively regulate apoptosis (31, 32). In our sys-
tem, IL-7 up-regulated Bcl-2, which is directly involved in
regulation of mitochondrial integrity. In addition, IL-7 in-
duced expression of Glut1, a regulator of glucose transport,
which indirectly controls mitochondrial integrity (32). For
these reasons, we analyzed the effect of IL-7 on mitochon-
drial homeostasis of TAIL7 cells. Mitochondrial homeosta-
sis can be evaluated by measuring mitochondrial membrane
potential (  m) using the potentiometric dye TMRE and
flow cytometry analysis (30). Initial analyses of the whole
cell population demonstrated that IL-7 up-regulated   m in
TAIL7 cells, and LY294002 completely abrogated this ef-
fect (Fig. 6 C). The percentage of TMRE high cells (Fig. 6
C, right peak of the histograms) was similar to the percent
of viable cells identified using annexin V/propidium iodide
staining (not depicted). Because differences in   m can be
measured even before early manifestations of apoptosis
(33), we next focused our analysis on the live population
(Fig. 6 D). IL-7–mediated up-regulation of   m on this
population was abrogated by LY294002 (Fig. 6 D), sug-
gesting that maintenance of mitochondrial integrity and
homeostasis is an early event in the regulation of PI3K-
dependent cell viability mediated by IL-7.
Discussion
IL-7 is expressed in the bone marrow and thymus and
has been shown to stimulate the expansion of immature
Figure 6. IL-7 regulates Glut1 expression and mitochondrial homeosta-
sis via PI3K activation. TAIL7 cells were cultured for 96 h under the indi-
cated conditions. (A) Cell lysates were resolved with 10% SDS-PAGE and
immunoblotted with anti-Glut1 antibody. Anti–ZAP-70 antibody was
used in the same membrane to ascertain even protein loading. (B) IL-7
promotes glucose uptake in a PI3K-dependent manner. TAIL7 cells were
cultured as indicated for 96 h. Cells were then assayed for glucose uptake
as described in Materials and Methods. (C) Mitochondrial membrane poten-
tial (  m) was assessed at 96 h of culture by staining TAIL7 cells with the
potentiometric dye TMRE and analyzing the whole population by flow
cytometry. TMRE intensity reflects the   m. Results are expressed as
MIF. (D) Viable cells were identified and selected by flow cytometry by
gating on the live cell population, as determined by FSC   SSC and/or
annexin V–FITC staining.   m of this population was determined using
TMRE. Results are representative of three independent experiments.Regulation of T-ALL Growth via PI3K–Akt 666
double negative and mature single positive thymocytes, in
part by up-regulating Bcl-2 expression and viability, and
also by inducing cell cycle progression (1, 33). In humans
and mice, defective IL-7R expression results in severe T
cell deficiency (34, 35), indicating that IL-7 plays an essen-
tial role during T cell ontogeny. Primary leukemic T cells
show increased proliferation (2) and viability (3) when cul-
tured with IL-7, suggesting that IL-7 might also be in-
volved in the pathobiology of T-ALL. Up-regulation of
cdk activity with consequent Rb hyperphosphorylation
and progression toward S phase are absolutely dependent
upon IL-7–induced down-regulation of p27kip1. In addi-
tion, p27kip1 down-regulation is associated with up-regula-
tion of Bcl-2, which in turn is essential for IL-7–mediated
survival of T-ALL cells (7).
Cytokines and growth factors can not only influence
survival, but also cell growth through effects on glucose
transporter expression, glucose uptake, and glycolysis (29,
30, 32). Lymphocytes require extrinsic stimulation to in-
duce expression of surface receptors such as Glut1 that pro-
mote nutrient uptake and increase metabolic activity (36).
TCR and IL-7R signals are among the signals that induce
Glut1 in mature T cells. The importance of these extrinsic
signals to promote nutrient intake in mature T cells was
originally revealed by the observation that Bcl-2 transgene
expression maintains cell survival, but does not prevent cell
atrophy resulting from limited energy supplies due to inad-
equate nutrient uptake (36, 37). In this study we demon-
strated that Glut1 is induced in high amounts in T-ALL
cells by IL-7 and that its expression is dependent on IL-7–
mediated signaling. In parallel with increased Glut1 expres-
sion, IL-7 also promoted nutrient uptake, increase of cell
size, activation, and subsequent cell cycle progression and
proliferation of T-ALL. Our results strongly suggest that
IL-7 signals are needed not only to promote survival of
leukemia cells by up-regulating Bcl-2, but also to provide
the means for the generation of metabolic energy for initi-
ating the cell cycle progression program that will eventually
lead to cellular proliferation and expansion.
We examined the signaling pathways that might link IL-7
to the downstream regulators of viability and cell cycle, par-
ticularly to Bcl-2, Glut1, and p27kip1. Knowledge regarding
IL-7–mediated pathways in T cells is rather incomplete and
very little is known about the integrity and biological role of
those pathways in T-ALL cells. PI3K–Akt and MEK–Erk
pathways have been associated with TCR- or cytokine-
mediated expansion of T cell precursors and mature T cells
(19, 20, 38). The PI3K–Akt pathway is activated by IL-7 in
normal T cells (18, 23). In contrast, most studies with pri-
mary human mature T cells and murine T cell lines have
shown that IL-7 does not mediate MEK–Erk activation
(23), nor does it phosphorylate the MEK–Erk upstream
molecules Shc (23, 39) and Ras (40). Our studies showed
that in T-ALL cells, IL-7 activates Erk1/2 in a time- and
dose-dependent manner that relies on MEK activity. How-
ever, inhibition of the MEK–Erk pathway does not affect
IL-7–mediated viability or cell cycle progression of TAIL7
cells, indicating that these events occur in a MEK–Erk-
independent manner. Studies in different cell types support
an active role for Ras and MEK–Erk in p27kip1 phosphoryla-
tion and consequent degradation by the ubiquitin–proteasome
system (41). In T-ALL cells we found that down-regulation
of p27kip1 protein expression and Rb hyperphosphorylation
that result from culture with IL-7 were not reverted by
MEK inhibition. Hence, although the MEK–Erk pathway
is activated by IL-7 in T-ALL cells, its exact biological role
remains to be determined.
Our studies showed that IL-7 induced phosphorylation
of Akt and its downstream targets GSK-3, FOXO1, and
FOXO3a in a PI3K-dependent manner, indicating the ex-
istence of a functional IL-7–mediated PI3K–Akt pathway
in T-ALL cells. Our subsequent studies with the PI3K in-
hibitor LY294002 demonstrated that activation of PI3K is
mandatory for Bcl-2 up-regulation, Glut1 induction, glu-
cose uptake, p27kip1 down-regulation, and Rb hyperphos-
phorylation in IL-7–cultured T-ALL cells. Accordingly,
IL-7 mediates cell cycle progression and viability of T-ALL
cells via PI3K-dependent signals. Several studies have
shown that engagement of the IL-7R induces activation of
PI3K and PI(3,4,5)P3 production in human thymocytes, T
lineage ALL blasts, and T-ALL cell lines (2, 40, 42), leading
to their survival and proliferation (2, 18, 40). However, the
exact PI3K-dependent mechanisms through which IL-7
exerts its effects in T cells are still under investigation. Al-
though we cannot rule out the possibility that other PI3K
downstream targets such as PKC or ILK (43, 44) might
contribute to IL-7–induced functional outcomes, we favor
the possibility that Akt is the main effector of IL-7–stimu-
lated PI3K in T-ALL. First, IL-7 induced phosphorylation
of FOXO1 and FOXO3a at threonine residues Thr24 and
Thr32, which are targets for Akt kinase activity. Second,
IL-7 induced phosphorylation of the Akt target GSK-3.
Phosphorylation of members of the Forkhead Box O
(FOXO) family of transcription factors FOXO1, FOXO3a,
and FOXO4 by Akt induces their inactivation and nuclear
export (25). FasL and p27kip1, which can be involved in
apoptosis, are transcriptionally up-regulated by FOXO
family members (25, 45). Thus, FOXO inactivation by the
PI3K–Akt pathway may contribute to down-regulation of
p27kip1 by IL-7. Phosphorylation of GSK-3 results in its in-
activation. Because active GSK-3 can mediate cell death,
inactivation of GSK-3 by phosphorylation may promote
cell viability (46). GSK-3  may also phosphorylate cyclin
D1 (47) and c-Myc (48), promoting their protein degrada-
tion and contributing to cell cycle arrest. In addition, GSK-3
can also phosphorylate and inhibit NF-ATc, a transcription
factor involved in proliferation (49, 50) and Bcl-2 gene
transcription (51). Thus, GSK-3 phosphorylation and sub-
sequent inactivation could result in up-regulation of Bcl-2
via activation of NF-ATc transcriptional activity (51) and
down-regulation of p27kip1 via c-Myc protein stabilization
(48, 52).
A drop in   m occurs very early during apoptosis (53).
We showed that IL-7 up-regulates   m in T-ALL cells in aBarata et al. 667
PI3K-dependent manner. This could be achieved via regu-
lation of Bcl-2 expression (54, 55). Another possible mech-
anism may involve IL-7–mediated induction of glucose
uptake and metabolism, which subsequently regulates mi-
tochondrial homeostasis and   m. Consistently with the
second mechanism, our results showed that IL-7 induced
Glut1 glucose transporter expression and glucose uptake.
Cytokine- or oncogene-induced glucose uptake appears to
regulate mitochondrial homeostasis, thereby maintaining
mitochondrial integrity and preventing apoptosis (31, 32).
Conversely, glucose depletion or inhibition of glucose up-
take is linked with cell death (31, 36). Here we showed
that IL-7 up-regulates the expression of the glucose trans-
porter Glut1 via PI3K activation. Thus, PI3K might con-
trol mitochondrial integrity and prevent apoptosis by regu-
lating both Bcl-2 expression and glucose metabolism in
T-ALL cells. Further studies are required to dissect the in-
dividual contribution of Bcl-2 and glucose metabolism in
IL-7–regulated mitochondrial homeostasis.
Our studies have shown that IL-7–mediated up-regula-
tion of Glut1 is associated with an increase in cell size. This
finding may have significant implications on T-ALL patho-
biology. Recent evidence suggests that there might be a
correlation between increased cell size and oncogenesis
(16). Moreover, tumor progression may not only depend
upon uncontrolled cell cycle progression, but also upon
unbalance of cell size regulatory mechanisms (56). Activa-
tion of lymphocytes is associated with increased size and
metabolic activity (28, 36). The transferrin receptor CD71
is up-regulated by lymphocytes upon activation as a mech-
anism to meet the increased iron demands associated with
increased metabolism (57). Increased Glut1 expression, glu-
cose uptake, and glycolytic rates mediated by external sig-
nals allow T cells to anticipate energetic and biosynthetic
needs associated with activation and cell growth (28). Our
study showed that IL-7 contributes to T-ALL cell growth
and activation, as shown by a dramatic increase in cell size
and surface expression of CD71 and CD69, which corre-
late with induction of Glut1 expression. All of these events
are dependent on PI3K activation. In mature T cells, the
PI3K–Akt pathway regulates glucose metabolism mediated
by CD28 costimulation (28), and Akt-controlled glucose
uptake can promote survival and cell growth in other cell
types (30, 58). Interestingly, in developing CD8  single
positive thymocytes, IL-7 up-regulates Glut1 expression
and glucose uptake (59).
There is mounting evidence that exogenous stimuli, par-
ticularly IL-7, may confer a selective advantage to leukemic
T cells and play a fundamental role in leukemia pathophys-
iology (3, 6, 7, 60–62). Our studies presented here showed
that IL-7–mediated activation of PI3K–Akt is not only es-
sential for increased viability, but also critically involved in
the regulation of metabolic activity, cell size, and prolifera-
tion of T-ALL cells, suggesting that this pathway may have
an indispensable role in T-ALL biology. Importantly, over-
activation of the PI3K–Akt pathway is associated with tu-
morigenesis (12, 16). Consistently, Jurkat and other T-ALL
cell lines lack expression of PTEN, a phosphatase that tar-
gets PI(3,4,5,)P3, and consequently have high constitutive
Akt activity (17). Taken together, our results support the
conclusion that PI3K is a pivotal mediator of IL-7 signaling
in T-ALL cells with a striking impact on several biological
mechanisms necessary for tumorigenesis. These observa-
tions indicate that PI3K and its downstream targets might
be essential for expansion of malignant T cells in vivo and
may represent molecular targets for pharmacological inter-
vention in T-ALL.
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